Anzeige
Mehr »
Login
Freitag, 06.08.2021 Börsentäglich über 12.000 News von 668 internationalen Medien
Relay Medical im Fokus der Sportwelt! Federer, Nadal & Medvedev...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KAVV ISIN: IE00B91XRN20 Ticker-Symbol: 0PT 
NASDAQ
05.08.21
22:00 Uhr
55,94 US-Dollar
0,00
0,00 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
PROTHENA CORPORATION PLC Chart 1 Jahr
5-Tage-Chart
PROTHENA CORPORATION PLC 5-Tage-Chart
RealtimeGeldBriefZeit
46,60047,80005.08.
47,00047,40005.08.
GlobeNewswire (Europe)
601 Leser
Artikel bewerten:
(2)

Prothena Corporation plc: Prothena to Participate in JMP Securities Life Sciences Conference on June 16

DUBLIN, Ireland, June 10, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Wednesday, June 16 at 3:00 PM ET

A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics, built on protein dysregulation expertise, with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and a number of other neurodegenerative diseases. For more information, please visit the Company's website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Investors & Media
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com


PROTHENA-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 GlobeNewswire (Europe)
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.